Acyl-CoA-Binding Protein Detection and Functional Analysis

Comprehensive Acyl-CoA-Binding protein detection and Functional Analysis for Metabolic Research, Drug Discovery, and Biomarker Development

Acyl-CoA-binding protein (ACBP) is a highly conserved 10‑kDa polypeptide that binds medium- and long-chain acyl-CoA esters with high affinity, playing a pivotal role in intracellular lipid trafficking, fatty acid oxidation, and membrane biosynthesis. ACBP also functions as a neuropeptide (diazepam-binding inhibitor) and a secreted hormone involved in appetite regulation and energy homeostasis. Dysregulation of ACBP expression and function has been implicated in metabolic disorders (obesity, diabetes, fatty liver disease), neurodegenerative conditions, and certain cancers, making ACBP a valuable target for both basic research and therapeutic intervention. The accurate, sensitive, and specific detection of ACBP—at the protein level, in terms of acyl-CoA binding capacity, and as a secreted factor—is essential for understanding its physiological roles, validating it as a biomarker, and screening modulators. Our specialized detection platform offers a comprehensive suite of validated biochemical and immunoassay services, delivering high-precision data that empower clients to elucidate ACBP function, monitor its levels in biological matrices, and accelerate drug discovery programs.

Understanding the Client's Need for Acyl-CoA-Binding Protein Analysis

Clients seeking ACBP detection services are typically driven by one or more of the following critical objectives: (i) quantifying ACBP protein levels in tissue homogenates, plasma, serum, or cerebrospinal fluid to evaluate its potential as a biomarker for metabolic or neurological diseases; (ii) assessing the binding affinity and specificity of ACBP toward various acyl-CoA species to understand substrate preferences and regulatory mechanisms; (iii) measuring the secretion of ACBP from cells or tissues to study its hormonal functions; (iv) evaluating the effect of drug candidates or genetic manipulations on ACBP expression and activity; (v) characterizing ACBP post-translational modifications (e.g., acylation, phosphorylation) that may modulate its function; and (vi) validating the purity and identity of recombinant ACBP preparations for research or therapeutic use. Our service is specifically designed to address these needs with scientific rigor, providing clients with a complete functional and molecular fingerprint of their ACBP samples.

Integrated Analytical Pipeline for Comprehensive ACBP Characterization

Our analytical platform is organized into four interconnected modules that collectively deliver a holistic evaluation of ACBP status. The Protein Quantitation and Isoform Module employs high-sensitivity ELISA (sandwich format) using monoclonal antibodies raised against human or rodent ACBP, providing LOQs as low as 0.05 ng/mL in plasma and 0.1 ng/mg in tissue lysates, with inter-assay precision < 5%. For absolute quantitation without antibodies, we use LC-MS/MS with parallel reaction monitoring (PRM) targeting unique tryptic peptides (e.g., LEEFLEK, KVEELK) with stable isotope-labelled internal standards, achieving LOQs in the low fmol/mg range and enabling the simultaneous detection of ACBP variants or degradation products. The Acyl-CoA Binding Module uses a fluorescence-based competitive binding assay with a fluorescent acyl-CoA analogue (e.g., BODIPY-C12-CoA) or a radiometric binding assay using ³H-oleoyl-CoA. We determine equilibrium dissociation constants (K_D) for a panel of acyl-CoAs (C14:0, C16:0, C18:1, C20:4) with precision within ±10% and LOD of 0.1 nM. For ligand screening, we offer a high-throughput fluorescence polarization (FP) assay with Z’-factors > 0.7. The Secretion and Cellular Module uses sandwich ELISA or electrochemiluminescence (MSD) to quantify ACBP in cell culture supernatants, and we perform flow cytometry for intracellular ACBP detection after cell permeabilization. We also offer immunohistochemistry (IHC) and immunofluorescence for tissue localization. The Post-Translational Modification Module employs LC-MS/MS with enrichment for phosphorylated or acylated peptides, using phosphopeptide enrichment (TiO₂) and acylated peptide enrichment by chemical capture, and we report site-specific modification stoichiometry with mass accuracy < 3 ppm. All modules are validated using recombinant ACBP standards and include rigorous quality controls (system suitability, matrix-matched calibration, and replicate analyses).

Unmatched Analytical Sensitivity, Specificity, and Mechanistic Resolution

Our platform consistently delivers performance that exceeds typical academic and industrial standards. In ELISA, we achieve signal-to-noise ratios > 200:1 at the LOQ, with linearity over four orders of magnitude. For PRM-based quantitation, our chromatographic gradient resolves ACBP peptides from all other proteins in complex matrices (plasma, liver, brain) with retention time reproducibility < 0.5% RSD and peak area precision < 4%. In binding assays, our FP method provides Z’-factors consistently > 0.7, and we perform competitive binding curves with 95% confidence intervals to determine IC₅₀ and K_i values. We also offer isothermal titration calorimetry (ITC) for thermodynamic profiling of ACBP-ligand interactions, yielding ΔH, ΔS, and binding stoichiometry with precision within ±2%. For modification analysis, we use high-resolution MS (Q-Exactive Orbitrap) to map modifications with site-specific confidence scores. Furthermore, we perform thermal shift assays (DSF) to assess ligand-induced stabilization of ACBP, providing T_m shifts with accuracy of ±0.2°C. This multi-parametric data set enables our clients to correlate protein abundance with binding activity, modification status, and cellular function, offering a systems-level understanding of ACBP biology.

Distinctive Advantages of Our Acyl-CoA-Binding protein detection Service

Our service provides several unique benefits that directly address client challenges. First, we have developed matrix-specific sample preparation protocols for a wide range of biological fluids and tissues—including plasma, serum, cerebrospinal fluid, urine, cell culture supernatants, and tissue homogenates—that effectively remove interfering lipids and proteins while preserving ACBP immunoreactivity, achieving recoveries of 92–105% for spiked standards. Second, we maintain a comprehensive reference database of ACBP sequences and modifications from human, mouse, rat, and other species, enabling rapid identification of expected peaks and accurate assignment of PTMs. Third, we offer a rapid screening service using a solid-phase ELISA that provides semi-quantitative ACBP levels within 2 hours of sample receipt—ideal for high-throughput clinical or experimental screening. Fourth, our customised ligand screening can test library compounds against ACBP binding, with IC₅₀ determination and mode-of-action analysis (competitive vs. allosteric) using our kinetic and binding assays. Fifth, we provide integrated data interpretation that links ACBP concentration, binding activity, and modification status to disease states or treatment responses—for example, correlating elevated plasma ACBP with insulin resistance, or identifying specific acyl-CoA species that show altered binding in mutant ACBP. Sixth, all our methods comply with ICH Q2(R1), CLSI, and ISO 17025 guidelines, and we supply full validation dossiers (specificity, linearity, accuracy, precision, LOD, LOQ, robustness) along with detailed SOPs, ensuring that our data are readily accepted by regulatory authorities and peer-reviewed journals. Our team of protein biochemists, mass spectrometrists, and clinical researchers provides consultative interpretation, helping clients to design follow-up experiments and to translate findings into clinical or drug development strategies.

Advanced Data Integration, Predictive Modeling, and Reporting

Our reporting transforms analytical data into actionable biomedical knowledge. We deliver a comprehensive final report that includes: (i) an executive dashboard with key metrics (ACBP concentration, K_D for acyl-CoAs, PTM stoichiometry, and cellular secretion rate) presented as concise scorecards; (ii) a detailed analytical section containing raw data, calibration curves, sensorgrams, chromatograms, and mass spectra; (iii) a statistical comparison of samples against control groups or historical data, with p-values and confidence intervals; and (iv) an interpretive narrative that contextualises the results—for example, explaining how a decreased K_D for a particular acyl-CoA may indicate a gain-of-function mutation, or how elevated secreted ACBP may be a sign of cellular stress. For clients with multiple time points or treatment groups, we provide trend analysis and multivariate clustering to reveal patterns. We also offer predictive models that estimate disease risk or therapeutic response based on ACBP profiles, using our internally developed machine learning algorithms. All raw data files (e.g., .xlsx, .raw, .cdf, .CSV) are supplied to ensure full transparency and re-analysis capability.

Broad Applications Across Metabolic Research, Neurology, and Drug Development

The versatility of our ACBP detection service spans a wide range of biomedical and pharmaceutical sectors. In metabolic disease research, our assays support the investigation of ACBP's role in obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). In neuroscience, our sensitive detection in CSF and brain tissue aids in understanding ACBP as a neuropeptide and its involvement in anxiety, appetite regulation, and Alzheimer's disease. In oncology, ACBP has been implicated in cancer cell metabolism and survival; our analyses help evaluate its potential as a target or biomarker. In drug discovery, our binding and screening modules accelerate the identification of ACBP modulators for therapeutic development. In clinical diagnostics, our validated ELISA and LC-MS/MS methods provide robust tools for large-scale biomarker validation. In academic research, our comprehensive biochemical and biophysical profiling supports publication-quality studies on ACBP structure-function relationships. Our ability to tailor the analytical package to the specific matrix, species, and research question ensures that we serve a diverse clientele with scientific rigor and efficiency.

Commitment to Innovation, Quality, and Client Partnership

We are dedicated to advancing ACBP analytics through continuous technological improvement. Our current R&D includes the development of lab-on-a-chip immunoassays for point-of-care ACBP detection, and the application of native mass spectrometry to probe ACBP-lipid interactions in near-physiological conditions. We actively participate in inter-laboratory proficiency testing for protein quantitation and lipid-binding assays, and we contribute to the development of reference materials for ACBP. Our quality management system is ISO 9001 and ISO 17025 certified, and we follow GLP for all regulatory studies. We offer flexible engagement models—from single‑sample analysis to long‑term collaborative projects—with dedicated project managers, volume discounts, and priority handling for time‑sensitive samples. Our global logistics provide specialised shipping kits (with protease inhibitors, preservatives) to preserve ACBP integrity during transit. Turnaround times range from 2 business days for rapid ELISA screening to 12 business days for comprehensive binding and PTM profiling. We maintain open communication, providing preliminary results upon request and final reports with expert commentary. Our success is measured by the confidence our clients have in their data and their ability to advance research and drug development. We invite you to partner with us to unlock the full potential of your acyl-CoA-binding protein analysis.

In summary, our acyl-CoA-binding protein detection service delivers a comprehensive, precise, and application‑oriented analytical solution that integrates protein quantitation, ligand-binding assessment, secretion monitoring, and PTM characterization. By combining advanced immunoassay and mass spectrometry platforms with deep expertise in lipid biochemistry, we empower our clients to elucidate ACBP function, validate biomarkers, and accelerate therapeutic discovery. We look forward to supporting your ACBP analysis needs with our state‑of‑the‑art analytical platform.